• Researcher Profile

    James M. Cleary, MD, PhD

     
    James M. Cleary, MD, PhD
     
    Physician

    Instructor in Medicine, Harvard Medical School

    Centers/Programs

    Early Drug Development Center
    Gastrointestinal Cancer

    Office phone: 617-632-6073
    Fax: 617-632-5370
    Email: jcleary@partners.org

    Preferred contact method: office phone

    View Physician Profile
     
     

    Interests

    Gastrointestinal malignancies, Phase 1 clinical trials

    Area of Research

    Early Drug Development, Gastrointestinal Malignancies, Translational Research

    Dana-Farber Cancer Institute
    450 Brookline Avenue
    LG-GC12
    Boston, MA 02215

    Research

    Early Drug Development, Gastrointestinal Malignancies, Translational Research

    My career is focused on phase 1 and proof-of-mechanism clinical trials that are testing new targeted therapies and novel therapeutic strategies. While I conduct trials appropriate for a broad range of solid tumors, I am particularly interested in new drug development for gastrointestinal malignancies. Currently, I am developing several protocols appropriate for specific molecularly defined patient cohorts, including those whose tumors are dependent on EGFR, mutant K-Ras and mutant B-Raf, respectively. I also interact with Dana-Farber translational researchers to understand and develop predictors of sensitivity and resistance to targeted agents that can be incorporated into patient selection for trials.

    Select Publications

    • Cleary JM, Sadow PM, Randolph GW, Palmer EL, Lynch TP, Nikiforov YE, Wirth LJ. Neoadjuvant Treatment of Unresectable Medullary Thyroid Cancer with Sunitinib. Journal of Clinical Oncology; In press
    • Cleary JM and Shapiro GI. Development of Phosphoinositide 3-kinase pathway inhibitors for advanced cancer. Current Oncol Rep 2010; 12:87-94
    • Cleary JM, Tanabe KT, Lauwers GY, Zhu AX. Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver. The Oncologist 2009; 14:1095-1105.
    • Cleary JM and Chabner BA. Angiogenesis inhibitors. In: Brunton L, Lazo J, Parker K, editors. Goodman and Gilmans The pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill. In press
View Researcher Directory
View Nurse Directory

Find a Clinical Trial

Support Cancer
Research

Give Now